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Summary 
The isolation,  characterization,  and expression of a full-length cDNA encoding the human T 
cell glycoprotein CD6 is described. COS calls transfected with the CD6 done express a 90-kD 
protein that reacts with all available anti-CD6 monoclonal antibodies. RNA blot hybridization 
analysis indicates that CD6 transcripts  are predominantly restricted  to cells in the T  lineage. 
The predicted CD6 sequence is 468 amino acids long, with the typical features of a type I integral 
membrane protein.  The cytoplasmic domain of CD6 contains two serine residues, one or both 
of which are substrates for phosphorylation during T cell activation. The extracdlular domain 
of CD6 is significantly related to the extracellular domain of the human and mouse T cell antigen 
CDS, the cysteine-rich domain of the bovine and mouse type I macrophage scavenger receptor, 
the extracellular domain of the sea urchin spermatozoa protein that crosslinks the egg peptide 
speract, the mammalian complement factor 1, and the human lung tumor antigen L3. These 
molecules,  therefore,  constitute a new gene superfamily that is well conserved across species 
boundaries. 
C 
D6 is a 100-130-kD glycoprotein expressed by periph- 
eral blood T lymphocytes, medullary thymocytes, a small 
number of peripheral blood B lymphocytes, as well as on some 
B cell chronic lymphocytic leukemias, and in some cells of 
the brain (1-6).  Although the physiological role of CD6 is 
not known, recent studies suggest that CD6 plays an impor- 
tant role in T cell activation.  The anti-CD6 mAb T12 can 
activate T  cells in a macrophage-dependent fashion (7). A 
second anti-CD6 mAb 2H1, has been shown to activate T 
cells in conjunction with PMA or the anti-CD2 mAb Tl13 
(2). These two mAbs recognize two distinct CD6 epitopes 
(7). The T12 epitope is present only under nondenaturing 
conditions,  while 2H1 recognizes an epitope which is un- 
affected by denaturation. Furthermore, 2H1 binding is only 
partially blocked by preincubating T cells with the T12 mAb, 
while T12 binding is not affected by pretreatment of T cells 
with the 2H1 mAb (7). It has been suggested that the differ- 
ence in  epitope  specificity of these  two  anti-CD6  mAbs 
accounts for their distinct activation properties (7). In vivo 
anti-CD6 mAbs (T12) have been shown to act as immunosup- 
pressive agents for patients undergoing renal or bone marrow 
allograft rejection (8, 9). In addition, preliminary studies in- 
dicate that anti-CD6 mAb might have immunomodulatory 
effects in patients with multiple sclerosis (10). 
Biochemical characterization of CD6 indicates that this pro- 
tein is a highly glycosylated cell surface molecule (7, 11). The 
addition of N-linked carbohydrate groups accounts for at least 
30 kD of the molecular mass of the protein (7, 11). Western 
blot analysis of the protein under reducing and nonreducing 
conditions suggests the presence of intrachain disulfide bonds 
(7). Activation of T cells results in the phosphorylation of 
the protein on cytoplasmic serine residues (7,  11,  12), but 
CD6 does not express any detectable kinase activity (7). 
Here we report the isolation and expression of two human 
CD6 cDNA clones. RNA blot hybridization analysis with 
RNA samples prepared from a number of T cell, B cell, and 
myeloid cell lines shows that CD6 transcripts are present pre- 
dominantly in T cells. Comparison of the predicted amino 
acid sequence of CD6 with that of other published proteins 
indicates that the extracellular domain of CD6 is homolo- 
gous to the members of a recently identified family of pro- 
teins which contain domains defined by the cysteine-rich do- 
main of type I macrophage scavenger receptor (13). 
Materials and Methods 
Preparation of eDNA Library and Recovery and Characterization of 
CD6 Clones.  Preparation  of a human peripheral  blood acute lym- 
phocytic leukemia (HPB-ALL) expression cDNA library in the 
shuttle vector wH3 was described  previously  (14, 15). The library 
was introduced  into COS cells by the spheroplast method, and was 
enriched for CD6 cDNAs by panning with a panel of anti-CD6 
mAbs obtained from the Second International Leukocyte  Typing 
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M-T604, M-T603, and CD6-9C4. After three rounds of introduc- 
tion into COS cells and panning, plasmid  DNA was prepared  from 
eight single  colony  isolates, transfected  into COS cells  by the DEAE- 
Dextran method and scored for CD6 expression  by indirect im- 
munofluorescence  as described  (14, 15). ,Additional  immunofluores- 
cence studies were carried out with mAb 2H1 which was a gift 
of Dr. C. Marimoto (Harvard Medical School, Boston, MA). 
Immunoprecipitation,  RNA  Blot  Hybridization,  and  DNA  Se- 
quencing.  Radioimmunoprecipitation,  RNA blot hybridization 
were carried  out as described  previously  (14, 15). Sequencing  was 
done by the dideoxy method (16). 
Protein Sequence Alignment.  Comparison  of the predicted  amino 
acid sequence  of CD6 with other proteins in the National Bio- 
medical  Research  Foundation  database  was done using the FASTP, 
Bestfit, and Compare  algorithms  available  in the University  of  Wis- 
consin Genetics Computer Group, sequence analysis software 
package (Madison, WI). 
Results and Discussion 
Two cDNA clones encoding the lymphocyte  glycoprotein 
CD6 (CD6-15 and CD6-13) were isolated from an expres- 
sion library as previously  described. COS ceUs  transfected  with 
these two cDNA clones reacted with all the anti-CD6 mAbs 
tested, as determined by indirect immunofluorescence (data 
not shown). Immunoprecipitation of cDNA-encoded pro- 
tein from transfected COS cells showed a single band of 90 
kD from COS cells transfected with the CD6-15 cDNA (Fig. 
1), and a broad band ranging from 58 to 80 kD from COS 
cells transfected with the CD6-13 cDNA. In both cases the 
COS cell-derived proteins are smaller than the protein ob- 
tained from the cell line HPB-ALL. We believe  that this differ- 
ence in size is the result of incomplete glycosylation of the 
protein by COS cells, a phenomenon that we have observed 
in the past  (15). 
RNA blot hybridization analysis revealed a single RNA 
species of ~  3 kb whose expression was restricted to T cells 
(data not shown). We found CD6 message in RNA isolated 
from: the T cell leukemia, HPB-ALL; and lymphokine stimu- 
lated peripheral blood T cells. No CD6 message was found 
in RNA isolated from: the T cell leukemia, Jurkat; the PMA 
stimulated or unstimulated promonocyte leukemia,  U937; 
the human erythroleukemia, HEL;  the hepatocarcinoma, 
HepG2; the amdanotic mdanoma, C32; the EBV-transformed 
B lymphoblastoid cell line, CESS; the pre-B cell leukemia, 
IM-9; the Burkitt lymphoma, Rail; and the plasmacytoma, 
RPMI 8226. 
The two cDNA clones contain inserts of 3 kb (CD6-15) 
and 1.4 kb (CD6-13), respectively. CD6-15 encodes a long 
open reading frame of 468 residues having the typical fea- 
tures of  an integral membrane protein (the nucleotide sequence 
is available  from EMBL, Genbank, and DDBJ data bases under 
accession  number X60992). Using the method of Von Heijne 
(1986) (17) we predict a 24 amino acid NH2-terminal signal 
sequence.  Removal  of the  NH2-terminal  signal  sequence 
results in a mature protein of 444-residues with a predicted 
Mr of 47.4 kD. In the extracellular domain there are eight 
N-linked glycosylation sites (Asn-X-Ser/Thr). This is in agree- 
ment with the biochemical characterization of CD6 by Swack 
Figure 1.  Surface  expression  of the CD6 antigen. Lane I; molecular 
mass standards.  Lanes  2-5; anti-CD6 mAb immunoprecipitates  of HPB- 
ALL cells,  COS cells  transfected  with CD6-15, COS cells  transfected  with 
CD6-13 and mock transfected  COS cells. 
et al. (1989, 1991) (7, 11), who showed that at least 30 kD 
of  the molecular mass can be attributed to N-linked glycosy- 
lation. The 374 amino acid extracellular domain of CD6 is 
followed by a 26 amino acid hydrophobic  membrane span- 
ning domain and a 44 amino acid cytoplasmic domain. There 
are two serine residues in the cytoplasmic domain, one or 
both of which could be phosphorylation substrates during 
T  cell activation  (7,  11,  12). 
Sequence analysis  of CD6-13 (data not shown) showed that 
it is missing "~ 1.5 kb of the 3' sequence relative to CD6-15. 
This results in a truncated protein, missing 23 amino acids 
of the cytoplasmic domain. The last amino acid in this trun- 
cated protein was encoded by sequences derived from the 
cloning vector which also provides an in-frame stop codon. 
This observation,  in conjunction with the tLNA blot anal- 
ysis (data not shown), which shows a single 3-kb species in 
RNA obtained from either T cells or the HPB-ALL cell line, 
indicate that the shorter clone was probably generated during 
the cloning procedure and does not represent a naturally oc- 
curring CD6 transcript. 
The predicted amino acid sequence of CD6-15 was com- 
pared with the National Biomedical Research Foundation 
(NBRF) database using the FASTP algorithm. Significant 
homology  was found with the human and mouse T cell sur- 
face protein CD5 (18, 19), the cysteine-rich domain of the 
bovine and mouse macrophage scavenger receptor type I (13, 
20), the extraceUular domain of the sea urchin spermatozoa 
protein responsible for crosslinking the egg peptide speract 
(21), the human complement factor 1 (22), and the human 
lung tumor antigen L3 (23) (Fig. 2). Over an •100  amino 
acid stretch (a region defined by the cysteine-rich domain of 
the macrophage scavenger receptor type I, StLCR) (13) six 
cysteine residues are shared with approximately equal spacing 
950  Molecular  Cloning of the CD6 Antigen Figure 2.  Homology  between the CD6 sequence  and human  CDS, the 
bovine macrophage  scavenger receptor type I (BOVINE-SR), the speract 
crosslinking  protein from sea urchin sperm (SPERACT), the human  com- 
plement factor I (CFI), and the human lung tumor antigen  L3 (L3). The 
CD6-1, 2, and 3 extracellular  domains correspond to residues (21-136), 
(137-240) and (241-341), respectively.  The CD5 extracellular  domains  1-3 
and the speract receptor  extracellular  domains  1-4 were  previously  described 
(13). Cysteine  residues shared by all of the SRCR family  members are 
denoted by a A, the two cysteine  residues shared only  by CD6 and CD5 
are denoted with a  ,/ 
by six of the seven members of the SRCR family. At the 
moment only a small number of residues  of the L3 antigen 
have been reported based on NH2-terminal sequence; further 
work is needed to confirm if the L3 sequence will fully con- 
form to that of the SRCR domain. Within this region we 
also find 31 highly conserved residues and two additional cys- 
teine residues  which are shared by CD6  and CD5 but are 
not present in the other members of the SRCR family. From 
this we conclude that CD6 and CD5 are more closely related 
to each other than to the other members of the SRCR family. 
The inclusion of CD5  in  the immunoglobulin supergene 
family has been controversial (24-26). This data and a recent 
report describing the homology between CD5 and the type 
I scavenger receptor (13) indicate that both CD6 and CD5 
are more closely related to the SRCR family than to the im- 
munoglobulin supergene family. 
Analysis of the sequence  of CD6 with a dot matrix ho- 
mology program showed that the extracellular domain of CD6 
is composed of three SRCR domains (Fig. 2). This repeated 
domain structure is also found in the other members of the 
SRCR family of proteins which are integral membrane pro- 
teins. The extracellular domain of CD5 is also composed of 
three SRCR motifs (13) while the extracellular region of the 
speract crosslinking protein is composed of four SRCR do- 
mains (13) (Fig.  2). Although the type I scavenger receptor 
gene encodes a single cysteine-rich domain, the protein is ex- 
pressed on the cell surface of macrophages as a trimer thereby 
bringing together three SRCR domains (20).  The human 
complement factor 1 protein contains a single SRCR domain 
(13) (Fig. 2) and the small amount of sequence information 
available for the L3 indicates that L3 contains at least one 
copy of the SRCR motif (Fig.  2). 
Based on the homology between the speract receptor and 
the other members of the SRCR family of proteins we have 
entertained the possibility that other membranes of this family 
are involved in peptide binding. Interestingly, the responses 
elicited by speract on its target cells are in some cases similar 
to those elicited by mAbs directed against CD6. For example, 
like speract, anti-CD6 mAbs can, under the appropriate con- 
ditions, cause increased  levels of intracellular Ca  2+  (27).  A 
number of different thymic peptide hormones which play 
a role in the recruitment of T cell precursors  to the thymus 
and in some steps ofintra- and extrathymic T cell differentia- 
tion and/or activation have been reported (29-31).  Receptors 
for these thymic peptides have yet to be identified. It is pos- 
sible that CD6 may be involved in the binding of thymus 
derived peptides. On the other hand, it is possible  that like 
CD5, CD6 is involved in protein binding (28).  CD72, the 
ligand of CD5 is a member of a large family of surface pro- 
teins with an inverted membrane orientation (32). Based on 
the homology between CD6  and CD5,  it is possible  that 
CD6 binds to one of the proteins in the CD72 gene super- 
family. The availability of cDNAs encoding CD6 will allow 
us to investigate these possibilities as well as others in an effort 
to understand the role of CD6  in the immune response. 
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